Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Harvard Business School
Express Scripts
Fish and Richardson
Boehringer Ingelheim
US Army

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 6,569,402

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,569,402
Title: Vitronectin receptor antagonist pharmaceuticals
Abstract:The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
Inventor(s): Cheesman; Edward H. (Lunenberg, MA), Barrett; John A. (Groton, MA), Carpenter, Jr.; Alan P. (Carlisle, MA), Rajopadhye; Milind (Westford, MA), Sworin; Michael (Tyngsboro, MA)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:09/599,365
Patent Claims:see list of patent claims

Details for Patent 6,569,402

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Eisai Inc ONTAK denileukin diftitox VIAL 103767 001 1999-02-05 ➤ Sign Up Bristol-Myers Squibb Pharma Company (Princeton, NJ) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 6,569,402

Country Patent Number Publication Date
South Africa 200004286 Aug 21, 2001
South Africa 200103675 Jun 07, 2002
World Intellectual Property Organization (WIPO) 0035488 Jun 22, 2000
World Intellectual Property Organization (WIPO) 0035488 Nov 09, 2000
World Intellectual Property Organization (WIPO) 0035492 Jan 18, 2001
World Intellectual Property Organization (WIPO) 0035492 Jun 22, 2000
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKesson
Cantor Fitzgerald
Citi
Express Scripts
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.